advertisement

Best Practices in Managing Patients with Heart Failure (HF) Collaborative

Through the Best Practices Learning Collaborative, organizations will be on the leading edge and have the opportunity to learn with other high-performing best practice organizations in a national forum. Together, they will improve care, deliver better value to patients, increase efficiency, and improve the health of their patients with heart failure (HF).

HF is a chronic disease that affects 5.1 million people in the United States. It’s the leading cause of hospitalization among adults 65 and older and costs are estimated at $32 billion a year. Total costs include healthcare services, medications to treat heart failure, and missed days of work. Admission rates following heart failure hospitalization remain high, with > 50% patients readmitted to hospital within six months of discharge, although there have been improvement in outcomes and medical therapy.

AMGA Foundation established the Best Practices in Managing Patients with Heart Failure Collaborative to bring together high performing health systems and medical groups to improve care, deliver better value to patients, increase efficiency, and improve the health of their patients with congestive heart failure (CHF).

The Collaborative consisted of 15 AMGA members participating in a yearlong collaborative to decrease hospital readmission rates and increase angiotensin –converting enzyme/angiostensin receptor blocker (ACE/ARB), Beta Blocker and angiotensin receptor neprilysin inhibitor (ARNI) utilization in patients with HF.

Best Practice Case Studies
AMGA worked together with the participating organizations to develop the Best Practices in Managing Patients with Heart Failure Compendium. The Compendium includes case studies from each of the medical groups, academic practices, and integrated delivery systems involved in the Collaborative.

HF Collaborative Case Studies

Best Practices in Managing Patients with Heart Failure Compendium is provided as an educational resource by AMGA and Novartis Pharmaceuticals Corporation.

Questions or Comments?
If you have questions or need further information, contact Danielle Casanova at dcasanova@amga.org or by phone at (703) 838-0033, ext. 347.